This systematic review examines the roles of interleukin-6 (IL-6) and interleukin-1β (IL-1β) in cardiovascular diseases (CVDs). The study analyzed 12 relevant studies published between 2014 and 2024, focusing on their association with adverse cardiovascular outcomes. Elevated levels of IL-6 were significantly linked to peripheral artery disease, myocardial infarction, and heart failure, while IL-1β levels were associated with worse outcomes in coronary artery disease and heart failure. Meta-analyses confirmed a significant association between higher levels of these cytokines and increased risk of adverse cardiovascular events. These findings suggest that targeting IL-6 and IL-1β could offer promising therapeutic strategies for reducing inflammation and improving cardiovascular outcomes. IL-6 is a multifunctional cytokine involved in immune response, inflammation, and hematopoiesis. It is produced by various cell types in response to infections and tissue injuries and stimulates the production of acute phase proteins like C-reactive protein (CRP), a clinical marker of inflammation. Elevated IL-6 levels are associated with increased risk of myocardial infarction, heart failure, and overall mortality in CVD patients. IL-6 not only reflects inflammatory status but also contributes to atherosclerosis by promoting endothelial dysfunction and plaque instability. IL-1β is a key pro-inflammatory cytokine involved in the progression of atherosclerosis and myocardial infarction outcomes. It is primarily produced by activated macrophages and promotes endothelial cell activation and leukocyte recruitment, accelerating the atherosclerotic process. Elevated IL-1β levels are associated with adverse outcomes in coronary artery disease and heart failure, highlighting its role in both the initiation and progression of atherosclerosis. Inhibition of IL-1β has shown promise in reducing recurrent cardiovascular events. Clinical trials have demonstrated that IL-1β inhibitors, such as canakinumab, significantly reduce recurrent myocardial infarction and other major adverse cardiovascular events. The review highlights the importance of inflammation in CVDs and suggests that targeting IL-6 and IL-1β could be a viable therapeutic strategy. Anti-inflammatory therapies targeting these cytokines have shown promise in reducing the inflammatory burden and improving cardiovascular outcomes. The CANTOS trial demonstrated that canakinumab, an IL-1β inhibitor, significantly reduced recurrent cardiovascular events in patients with a history of myocardial infarction. Similarly, colchicine, an anti-inflammatory drug, has shown efficacy in reducing the risk of recurrent ischemic cardiovascular events in patients with a recent myocardial infarction. The study also emphasizes the need for further research to optimize treatment strategies and develop personalized medicine approaches. Future research should focus on elucidating the mechanistic pathways through which IL-6 and IL-1β contribute to CVD progression and evaluating the efficacy of cytokine inhibitors in diverse patient populations. Personalized approaches, tailored basedThis systematic review examines the roles of interleukin-6 (IL-6) and interleukin-1β (IL-1β) in cardiovascular diseases (CVDs). The study analyzed 12 relevant studies published between 2014 and 2024, focusing on their association with adverse cardiovascular outcomes. Elevated levels of IL-6 were significantly linked to peripheral artery disease, myocardial infarction, and heart failure, while IL-1β levels were associated with worse outcomes in coronary artery disease and heart failure. Meta-analyses confirmed a significant association between higher levels of these cytokines and increased risk of adverse cardiovascular events. These findings suggest that targeting IL-6 and IL-1β could offer promising therapeutic strategies for reducing inflammation and improving cardiovascular outcomes. IL-6 is a multifunctional cytokine involved in immune response, inflammation, and hematopoiesis. It is produced by various cell types in response to infections and tissue injuries and stimulates the production of acute phase proteins like C-reactive protein (CRP), a clinical marker of inflammation. Elevated IL-6 levels are associated with increased risk of myocardial infarction, heart failure, and overall mortality in CVD patients. IL-6 not only reflects inflammatory status but also contributes to atherosclerosis by promoting endothelial dysfunction and plaque instability. IL-1β is a key pro-inflammatory cytokine involved in the progression of atherosclerosis and myocardial infarction outcomes. It is primarily produced by activated macrophages and promotes endothelial cell activation and leukocyte recruitment, accelerating the atherosclerotic process. Elevated IL-1β levels are associated with adverse outcomes in coronary artery disease and heart failure, highlighting its role in both the initiation and progression of atherosclerosis. Inhibition of IL-1β has shown promise in reducing recurrent cardiovascular events. Clinical trials have demonstrated that IL-1β inhibitors, such as canakinumab, significantly reduce recurrent myocardial infarction and other major adverse cardiovascular events. The review highlights the importance of inflammation in CVDs and suggests that targeting IL-6 and IL-1β could be a viable therapeutic strategy. Anti-inflammatory therapies targeting these cytokines have shown promise in reducing the inflammatory burden and improving cardiovascular outcomes. The CANTOS trial demonstrated that canakinumab, an IL-1β inhibitor, significantly reduced recurrent cardiovascular events in patients with a history of myocardial infarction. Similarly, colchicine, an anti-inflammatory drug, has shown efficacy in reducing the risk of recurrent ischemic cardiovascular events in patients with a recent myocardial infarction. The study also emphasizes the need for further research to optimize treatment strategies and develop personalized medicine approaches. Future research should focus on elucidating the mechanistic pathways through which IL-6 and IL-1β contribute to CVD progression and evaluating the efficacy of cytokine inhibitors in diverse patient populations. Personalized approaches, tailored based